NCT01844323View on ClinicalTrials.gov

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Healthy
Interventions
OTHER

Palbociclib Formulation Reference

Single 45 mg dose; Dosage form is capsule taken orally.

OTHER

Palbociclib Formulation Test

Single 45 mg dose; Dosage form is capsule taken orally.

OTHER

Palbociclib Formulation Test

Single 45 mg dose; Dosage form is capsule taken orally.

OTHER

Palbociclib Formulation Test

Single 45 mg dose; Dosage form is capsule taken orally.

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01844323 - A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract | Biotech Hunter | Biotech Hunter